Osvaldo Rudy Aren

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.3K citations · Full text

Medicine, Oncology, Pharmacology +15

Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non–Small-Cell Lung Cancer

Giorgio V. Scagliotti, Silvia Novello, Joachim von Pawel et al. · Journal of Clinical Oncology · 2010 · 454 citations · Full text

Medicine, Oncology, Pharmacology +17

Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial

Ian F. Tannock, Karim Fizazi, Camilla Thellenberg Karlsson et al. · The Lancet Oncology · 2013 · 287 citations

Medicine, Oncology, Pharmacology +16

Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial

Nasser H. Hanna, R. Kaiser, Richard N. Sullivan et al. · Lung Cancer · 2016 · 87 citations

Medicine, Oncology, Pharmacotherapy +11

Lume-lung 2: A multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy.

Nasser H. Hanna, R. Kaiser, Richard N. Sullivan et al. · Journal of Clinical Oncology · 2013 · 83 citations

Medicine, Oncology, Pharmacology +16